A new therapy was approved by the FDA on Thursday as a treatment for the partial onset of epileptic seizures in adults. Xcopri, or cenobamate, will be marketed by SK Life Science and will be launched by the second quarter of 2020.
Cenobamate gains FDA approval for partial-onset seizures in adults with epilepsy
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.